Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Better Communication, Better Care Using SICG Assistant Based on Artificial Intelligence (SICG-Assist)

4 de agosto de 2026 atualizado por: Cudeca Hospice Foundation

Improving Care for Cancer Patients by Facilitating Communication With Clinicians Through a Serious Illness Communication Program Using an Assistant Based on Artificial Intelligence.

The project 'Better Communication, Better Care' has as its main objective to evaluate the effectiveness of the implementation of the 'Guide to conversation in serious illness (SICG)' by means of a significant reduction in anxiety and depression index in patients with serious illness and their families. Additionally, it aims to explore the perceived utility of this guide from the perspective of patients, families, and healthcare professionals involved in Palliative Care. Another important objective is to assess the effectiveness of the training program to improve communicative competencies of healthcare professionals in real clinical contexts. Furthermore, the project is structured around a pragmatic randomized clinical trial by clusters, where healthcare professionals will be randomized into intervention and control groups, with patients being the unit of analysis. In parallel, a feasibility and usability study of the mobile application and virtual assistant that will support the implementation of the guide will be conducted, evaluating parameters such as learning facility, satisfaction, efficiency, and errors through validated instruments. Finally, a cost-benefit analysis will be carried out to determine the economic efficiency of the program in terms of resource optimization and improvement in care quality.

Visão geral do estudo

Status

Ativo, não recrutando

Intervenção / Tratamento

Descrição detalhada

Communication is a cornerstone of person-centered care, and takes on particular importance in serious illness, defined here as a condition carrying a high risk of mortality that negatively affects quality of life or daily functioning and that commonly produces significant emotional distress in caregivers. Inadequate, delayed, or infrequent communication contributes to avoidable patient and family suffering, and clinicians often lack structured tools and training to conduct high-quality conversations about goals, values, and preferences in serious illness.

The Serious Illness Conversation Guide (SICG), originally developed and validated internationally, provides a structured framework that clinicians can use throughout the course of an illness to elicit patient values and preferences and align care accordingly. This project - conducted by a research team that collaborates directly with the guide's original international developer group - will implement the SICG in routine clinical practice across primary care and hospital-based palliative care services in the province of Málaga, Spain, supported by a purpose-built mobile application and virtual assistant designed to facilitate documentation and continuity of the conversation across multiple involved clinicians.

The study combines four complementary components:

Cluster-randomized controlled trial (quantitative, confirmatory): Healthcare professionals (HCPs) are randomized (block randomization, blocks of 4) into an intervention arm (trained in and using the SICG, supported by the app/virtual assistant) or a control arm (usual care). Patients and families are recruited by their assigned HCP and constitute the unit of analysis (multilevel/mixed-model analysis accounting for clustering at the HCP level).

Before-after evaluation of HCP communication skills and satisfaction following SICG training.

Feasibility and usability study of the mobile application and virtual assistant, using the System Usability Scale (SUS, Spanish-validated) and the mHealth App Usability Questionnaire (MAUQ).

Cost-utility analysis from the funder's perspective (1-year time horizon), estimating incremental cost-effectiveness based on training costs, implementation costs, and healthcare resource utilization (emergency and hospital admissions, palliative care referrals).

A parallel qualitative strand (individual/group narrative interviews with HCPs, patients, and family key informants) will explore perceived utility of the SICG and document emergent experiences during implementation, analyzed thematically using an iterative, constructionist approach (NVivo).

Ethical approval for evaluation of the SICG implementation has been granted by the Comité de Ética de Investigación Provincial de Málaga (session of 30/09/2021); an amendment is planned to extend approval to cover use of the supporting mobile application (feasibility study component).

Study Design Field Value Study Type Interventional Study Design Pragmatic cluster-randomized controlled trial (mixed-methods) Allocation Randomized (block randomization at HCP level, blocks of 4) Intervention Model Parallel assignment Randomization Unit Healthcare professional (cluster) Unit of Analysis Patient Masking None (open-label; not feasible to blind HCPs to guide use) Primary Purpose Supportive care / Health services research Estimated Cluster Size ~5 patients per HCP Number of Clusters 40 HCPs (20 intervention / 20 control) Condition/Disease

Serious illness (advanced/life-limiting disease with high mortality risk and significant impact on quality of life); Palliative Care

Intervention

Experimental arm: Complex two-phase intervention - (1) Training of HCPs in use of the SICG (structured communication skills course); (2) Use of the SICG by trained HCPs with patients and their families (approx. 5 patients/families per HCP), supported by a dedicated mobile application and virtual assistant.

Control arm: Standard/usual care (no SICG training or use).

Eligibility Criteria

Patients:

Serious illness as defined above Age 18-80 years Spanish as native language Karnofsky Performance Status ≥50, or ECOG Performance Status ≤2, or Palliative Performance Scale (PPS) ≥50 Signed informed consent

Family members:

Family member of an eligible patient with serious illness Age 18-80 years Spanish as native language Signed informed consent

Exclusion criteria (patients and family members): Cognitive or perceptual impairment precluding completion of study questionnaires.

Healthcare professionals (HCPs):

Inclusion: Specialists in Palliative Care, Oncology, Hematology, or Primary Care, affiliated with Fundación CUDECA, Servicio Andaluz de Salud, or Institut Català d'Oncologia Exclusion: Any professional not meeting inclusion criteria Sample Size

190 patients with serious illness, calculated to detect a between-group difference of 2.5 points in anxiety/depression scores, with 95% confidence and 80% power, accounting for a design effect of 1.2 and an intracluster correlation coefficient (ICC) of 0.05. Patients recruited via 40 HCPs, average cluster size of 5.

Outcome Measures

Primary Outcome:

Change in anxiety and depression levels (Hospital Anxiety and Depression Scale, HADS) in patients and family members, intervention vs. control group.

Secondary Outcomes:

Perceived usefulness of the SICG (patients, families, HCPs) HCP communication skills and self-efficacy (validated communication self-confidence and expected-outcomes scales; psychosocial aspects of patient care scale) SICG implementation process fidelity and reach (patient identification/referral criteria; number of eligible vs. enrolled patients) Quality of life (EuroQoL-5D-5L; QLQ-C15-PAL) Cost-utility of SICG implementation (incremental cost-effectiveness ratio) Additional patient measures: Karnofsky Index, PPS, PS, Edmonton Symptom Assessment Scale (ESAS), Distress Thermometer App/virtual assistant usability and feasibility (SUS, MAUQ; learnability, efficiency, error rate, user satisfaction, engagement) Data Collection & Analysis

Quantitative data collected via electronic case report form (REDCap, hosted by Instituto IBIMA). Qualitative data collected via audio-recorded interviews, transcribed and analyzed in NVivo. Quantitative analysis by intention-to-treat; multilevel modeling to account for clustering at the HCP level; ICC calculated for the primary outcome; repeated-measures ANOVA for within-group change over time; multivariate imputation for missing data; significance threshold p<0.05 (two-sided); SPSS v25.0.

Estimated Timeline Recruitment of HCPs and training: approx. 8 months SICG implementation and follow-up: minimum 12 months per participating HCP Utility interviews: two time points during implementation Total estimated project duration: 36 months Data Sharing / Repository

De-identified data intended for deposit in a public repository (RIUMA - Universidad de Málaga institutional repository) following FAIR principles, subject to data protection regulations (GDPR; Spanish LOPDGDD 3/2018). Minimum 10-year data availability guaranteed by the research team.

Tipo de estudo

Intervencional

Inscrição (Estimado)

190

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

    • Málaga
      • Benalmádena, Málaga, Espanha, 29631
        • Fundación CUDECA
      • Benalmádena, Málaga, Espanha, 29631
        • CUDECA Institute/CUDECA Foundation

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

  • Adulto
  • Adulto mais velho

Aceita Voluntários Saudáveis

Não

Descrição

Inclusion Criteria:

  • Adults aged 18-80 years.
  • Diagnosis of a serious illness, defined as an illness carrying a high risk of mortality that negatively impacts quality of life or daily functioning, and that typically causes significant emotional distress in caregivers.
  • Karnofsky Performance Status ≥ 50 or Performance Status ≤ 2 or Palliative Performance Scale ≥ 50.
  • Spanish as native/fluent language, sufficient to complete the study questionnaires.
  • Cared for by an HCP enrolled in the study (intervention or control arm).
  • Able and willing to provide written informed consent.

Exclusion Criteria:

  • Cognitive or perceptual impairment that prevents reliable completion of the study questionnaires.
  • Inability to communicate in Spanish to the level required by the assessment instruments.
  • Any condition that, in the investigator's judgment, makes participation unsafe or unfeasible (e.g., clinical instability incompatible with follow-up).

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Cuidados de suporte
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição sequencial
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Sem intervenção: Usual Care group
Usual care. the subject recieve the usual care
Experimental: SICG Group
The SICG Group recieved the intervention of the study. As this is a cluster trial, the intervention operates at two levels. In the case of healthcare professionals, the experimental arm receives training in the use of the SICG for subsequent use with their patients. For patients, the experimental group receives the intervention through healthcare professionals' use of the SICG to explore their wishes and expectations regarding their care.
The intervention combines a structured serious illness communication guide with an AI-powered virtual assistant app. Unlike standard communication training, the app provides real-time support during clinical encounters: it records conversations automatically, suggests unexplored topics to the clinician, and enables post-visit discourse analysis to anticipate patient needs and predict clinical events. Healthcare professionals receive training in the use of the guide and app. Effectiveness is evaluated through a pragmatic cluster-randomized controlled trial (unit of randomization: HCP; unit of analysis: patient), a before-after design assessing HCP communication skills and satisfaction, a feasibility study using SUS and MAUQ questionnaires, and a cost-utility analysis over a one-year horizon. Qualitative data are collected via narrative interviews with HCPs and patient/family key informants to capture implementation experiences and emergent causal pathways.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Change in patient anxiety and depression
Prazo: Baseline, 1 month, 3 months, and 6 months after SICG conversation (or equivalent index visit in the control arm).
Change from baseline in Hospital Anxiety and Depression Scale (HADS) score in patients with serious illness, comparing intervention arm (care delivered by HCPs trained in the Serious Illness Conversation Guide [SICG]) vs. control arm (standard care). HADS comprises 14 items (7 anxiety, 7 depression), each scored 0-3; subscale range 0-21. Higher scores indicate worse symptoms. A between-group difference of 2.5 points is considered clinically relevant.
Baseline, 1 month, 3 months, and 6 months after SICG conversation (or equivalent index visit in the control arm).

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Change in family-caregiver anxiety and depression
Prazo: Baseline, 3 months, and 6 months after the patient's SICG conversation.
Change from baseline in HADS score among family caregivers of enrolled patients. Same scoring as above (range 0-21 per subscale; higher = worse).
Baseline, 3 months, and 6 months after the patient's SICG conversation.
Patient health-related quality of life (EuroQoL-5D-5L)
Prazo: Baseline, 3 months, and 6 months.
Change in EQ-5D-5L index value (utility score, range -0.594 to 1.000; higher = better QoL) and EQ-VAS (0-100). Used both as a clinical outcome and as the utility metric for the cost-utility analysis (QALYs).
Baseline, 3 months, and 6 months.
Patient cancer-specific quality of life (EORTC QLQ-C15-PAL)
Prazo: Baseline, 3 months, and 6 months.
Change in QLQ-C15-PAL, the 15-item palliative-care short form of the QLQ-C30. Functional and symptom subscales linearly transformed to 0-100.
Baseline, 3 months, and 6 months.
Family-caregiver health-related quality of life (EuroQoL-5D-5L)
Prazo: Baseline, 3 months, and 6 months.
Change in EQ-5D-5L index and EQ-VAS in family caregivers.
Baseline, 3 months, and 6 months.
Patient symptom burden (ESAS)
Prazo: Baseline, 1 month, 3 months, and 6 months.
Change in Edmonton Symptom Assessment System total distress score (10 symptoms, each 0-10; total 0-100; higher = worse).
Baseline, 1 month, 3 months, and 6 months.
Patient and caregiver distress (Distress Thermometer)
Prazo: Baseline, 1 month, 3 months, and 6 months.
Change in NCCN Distress Thermometer score (single-item visual analogue, 0-10; ≥4 = clinically significant distress).
Baseline, 1 month, 3 months, and 6 months.
Patient functional status (Karnofsky Performance Status / Palliative Performance Scale)
Prazo: Baseline, 3 months, and 6 months.
Change in Karnofsky Performance Status (0-100, higher = better function) and Palliative Performance Scale (0-100% in 10% decrements). Used both as descriptive variables and as eligibility-confirmation measures (KPS ≥50 or PPS ≥50 at enrolment).
Baseline, 3 months, and 6 months.
Patient and family satisfaction with SICG
Prazo: Within 2 weeks after the SICG conversation.
Ad-hoc satisfaction questionnaire on the use and perceived helpfulness of the Serious Illness Conversation, administered after the index conversation. more satisfaction better care.
Within 2 weeks after the SICG conversation.
HCP communication self-efficacy and attitudes (pre-post training)
Prazo: Baseline (pre-training), immediately post-training, and 6 and 12 months after training.
Change in three validated scales administered to participating healthcare professionals: (a) Self-Efficacy in Communication Skills scale; (b) Expected Outcomes of Communication scale; (c) Psychosocial Aspects of Patient Care scale. Higher scores indicate greater confidence, more positive expectations, and greater attention to psychosocial care, respectively.
Baseline (pre-training), immediately post-training, and 6 and 12 months after training.
HCP satisfaction with SICP training and implementation
Prazo: Immediately after training and 12 months after the start of SICG implementation.
Ad-hoc satisfaction questionnaire on the SICP training programme and on the experience of implementing the SICG in routine practice. Better score better satisfaction.
Immediately after training and 12 months after the start of SICG implementation.
Healthcare resource utilization
Prazo: From index conversation through 6 months of follow-up.
Number and type of contacts with healthcare services during the 6 months following the index conversation, extracted from electronic health records: emergency-department visits, hospital admissions and length of stay, outpatient visits, and referrals to specialist palliative care.
From index conversation through 6 months of follow-up.

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Publicações Gerais

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

1 de janeiro de 2026

Conclusão Primária (Estimado)

31 de outubro de 2028

Conclusão do estudo (Estimado)

31 de dezembro de 2028

Datas de inscrição no estudo

Enviado pela primeira vez

27 de abril de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

4 de agosto de 2026

Primeira postagem (Real)

7 de agosto de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

7 de agosto de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

4 de agosto de 2026

Última verificação

1 de abril de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever